Drug Profile
Research programme: monoclonal antibody therapeutics - Trellis Bioscience/Open Monoclonal Technology
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Open Monoclonal Technology; Trellis Bioscience
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 09 Oct 2012 Early research in Cancer in USA (Parenteral)